This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Water as Therapy in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

This study has been completed.
Information provided by (Responsible Party):
University of Kansas Medical Center ( University of Kansas ) Identifier:
First received: September 24, 2008
Last updated: February 24, 2012
Last verified: February 2012
Autosomal dominant polycystic kidney disease (ADPKD) is the most common single gene disorder that is potentially fatal. ADPKD is caused by mutations in either of two genes (PKD1, PKD2). Cysts begin to develop primarily in renal collecting tubules in utero and continue to form and expand throughout the patient's life. One of the goals of the study is to formulate a water prescription for use in clinical trials to determine the effect of sustained water diuresis on the progression of ADPKD.

Condition Intervention
Autosomal Dominant Polycystic Kidney Disease Other: Water prescription

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Water as Therapy in Autosomal Dominant Polycystic Kidney Disease

Resource links provided by NLM:

Further study details as provided by University of Kansas Medical Center ( University of Kansas ):

Primary Outcome Measures:
  • Percentage of mean urine osmolality decreased from baseline [ Time Frame: Day 3, 4, 5 ]

Secondary Outcome Measures:
  • Number of individuals who have an average daily solute excretion within 16.5% of baseline [ Time Frame: End of study ]
  • Number of individuals whose average total urine volume is within 18% of baseline. [ Time Frame: End of study ]

Enrollment: 11
Study Start Date: September 2008
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Water prescription
Other: Water prescription
Water prescription in 12 to 16 equally divided doses

Detailed Description:
The proposed study will devise a quantitative model to estimate the amount of water an individual would need to ingest in order to lower the 24 h mean urine osmolality to a level below plasma (~285 mOsm/Kg). This osmolality goal is chosen because the 24h median urine osmolality of humans is ordinarily ~753 mOsm/Kg, much greater than 285 mosm/Kg (6, 7). In other words, normal humans are usually anti-diuretic during waking hours and while asleep. Median 24h urine volume is ~1225 ml (range 1051 - 2270). In temperate climates the insensible losses of water in sweat, respiration and stool are nearly balanced by the water ingested in solid and semi-solid foods and derived from metabolism. Thus, daily urine volume measured upon arising in the morning is a reasonably good indicator of the volume of fluids drunk over the preceding 24 h.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ADPKD verified by ultrasound, CT or MRI, family history or physical exam
  • Normal creatinine clearance, calculated by Cockroft-Gault formulat
  • Good general health
  • Controlled blood pressure, < 140/90
  • Absence of urinary tract symptoms such as dysuria, hesitancy, diminished flow

Exclusion Criteria:

  • Azotemia
  • Uncontrolled hypertension
  • Urinary tract symptoms, dysuria, hesitancy, diminished flow, gross hematuria
  • Diabetes mellitus, cancer, hematologic disorder
  • Unable to follow directions
  • Solitary kidney
  • History of CHF, liver dysfunction or hyponatremia
  • Currently taking diuretics
  • Nephrotic range proteinuria (3.5 g/day)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00759369

United States, Kansas
University of Kansas Medical Center
Kansas City, Kansas, United States, 66160
Sponsors and Collaborators
University of Kansas
Principal Investigator: Connie Wang, MD University of Kansas Medical Center
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: University of Kansas Identifier: NCT00759369     History of Changes
Other Study ID Numbers: 11451
Study First Received: September 24, 2008
Last Updated: February 24, 2012

Keywords provided by University of Kansas Medical Center ( University of Kansas ):

Additional relevant MeSH terms:
Kidney Diseases
Polycystic Kidney Diseases
Polycystic Kidney, Autosomal Dominant
Urologic Diseases
Kidney Diseases, Cystic processed this record on September 21, 2017